Vigabatrin in the treatment of epilepsy caused by cortical developmental disorders

Abstract

Introduction. We present a case series diagnosed with cortical developments disorders on vigabatrin treatment. Objetive. The study aims to evaluate the effectiveness in terms of crisis control these patients, according to histological findings and functional disorders caused by tuberous sclerosis..
Materials and methods. We reviewed records of patients diagnosed with cortical developmental disorder treated with Vigabatrin, in the period between 2005 to 2008 at the Liga central contra la epilepsia Bogotá, Colombia. Data about type of disturbance of cortical development, classification of epilepsy, treatment before and after treatment with vigabatrin and presence of adverse effects.
Results. We reviewed 14 records, being 57.11% males, aged between 4 and 28 years. The most common form of epilepsy was the focal of a different location and type of cortical malformation was the most common focal cortical dysplasia.
The response obtained in terms of seizure control in 50% of the patients was over 90% with respect to seizure frequency prior to the start of vigabatrin. Only one patient showed clinically decreased visual field and improved with the cessation of treatment.
Conclusion. Vigabatrin is an effective and safe treatment for the management of patients with epilepsy secondary to cortical development disorders. Should closely monitor the possible occurrence of adverse effects.